意大利黑色素瘤患者队列中CDKN2A胚系突变与不良生存无关
在意大利高突变率黑色素瘤队列中,106例CDKN2A胚系突变阳性(MUT+)患者与199例按年龄、性别匹配且肿瘤分期分布相似的突变阴性(MUT-)散发性黑色素瘤患者相比,总生存(HR 0.85;95%CI 0.48-1.52;P=.592)和黑色素瘤特异性生存(HR 0.86;95%CI 0.38-1.95;P=.718)均无差异;MUT+患者更易发生多发性黑色素瘤并接受发育不良痣手术切除。
要点
- MUT+与MUT-患者总生存无差异(HR 0.85;95%CI 0.48-1.52;P=.592)。
- MUT+与MUT-患者黑色素瘤特异性生存无差异(HR 0.86;95%CI 0.38-1.95;P=.718)。
- MUT+患者更易发生多发性黑色素瘤并接受发育不良痣手术切除。
核心结论
- CDKN2A突变在本队列中与生存无关。
研究设计与样本
- 回顾性研究,共1239例皮肤黑色素瘤患者检测CDKN2A突变状态,并按家族史及突变状态分配随访方案。
- 从队列中选取106例MUT+患者(家族性黑色素瘤或表观散发性黑色素瘤)与199例MUT-散发性黑色素瘤患者,按年龄和性别匹配且肿瘤分期分布相似。
主要发现
- MUT+与MUT-患者总生存无差异(HR 0.85;95%CI 0.48-1.52;P=.592)。
- MUT+与MUT-患者黑色素瘤特异性生存无差异(HR 0.86;95%CI 0.38-1.95;P=.718)。
- MUT+患者较MUT-患者更易发生多发性黑色素瘤并接受发育不良痣手术切除。
临床怎么用
- 原文未据此给出推荐。
局限性
- 回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cyclin dependent kinase inhibitor 2A gene (CDKN2A) germline mutations have recently been associated with poor survival in patients with melanoma. Despite the high mutation rate in our cohort (up to 10% in patients with apparently sporadic melanoma), information on the impact of CDKN2A on survival in this cohort is lacking. OBJECTIVE: To investigate whether poor survival associated with CDKN2A germline mutations was confirmed in a high mutation-prevalence cohort of Italian patients with melanoma undergoing a mutation-based follow-up. METHODS: A total of 1239 patients with cutaneous melanoma were tested for CDKN2A mutational status and then assigned to a follow-up scheme according not only to family history but also to CDKN2A mutational status, as follow-up intervals were more frequent for CDKN2A germline mutation-positive (MUT+) patients. From this cohort, we selected 106 MUT+ patients (with familial melanoma or apparently sporadic melanoma) and 199 CDKN2A germline mutation-negative (MUT-) patients with sporadic melanoma who were matched by age and sex and had a similar tumor stage distribution. RESULTS: We found no difference in overall survival (hazard ratio, 0.85; 95% confidence interval, 0.48-1.52; P = .592,) or melanoma-specific survival (hazard ratio, 0.86; 95% confidence interval, 0.38-1.95; P = .718,) between MUT+ and MUT- patients. MUT+ patients were more likely to develop multiple melanomas and to undergo surgical excision of dysplastic nevi than were MUT- patients. LIMITATIONS: Retrospective study. CONCLUSION: CDKN2A mutations were not associated with survival in our cohort.
引用
- Dalmasso B, Pastorino L, Ciccarese G, et al. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients. J Am Acad Dermatol. 2018. PMID: 30274933. doi:10.1016/j.jaad.2018.07.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。